fda peptide regulations bpc-157 igf-1 cerebrolysin Comments Peptides for injury recovery are

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide

These conditions often involve chronic low-grade inflammation, cartilage degradation, and synovial fluid changes

Non-B12 causes of persistent symptoms with a high result When symptoms persist and the B12 is high, the symptoms may have nothing to do with B12 at all

The evidence isn't yet at the level of a treatment guideline

But as a reactive treatment for acute inflammation, infection, or wounds, dosing should end once the condition has resolved